BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36418865)

  • 21. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer.
    Moertel CG; O'Fallon JR; Go VL; O'Connell MJ; Thynne GS
    Cancer; 1986 Aug; 58(3):603-10. PubMed ID: 3731019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
    Moretto R; Rossini D; Conca V; Lonardi S; Rasola C; Antoniotti C; Santini D; Marmorino F; Tomasello G; Borelli B; Caponnetto S; Zucchelli G; Zaniboni A; Ambrosini M; Buonadonna A; Fanchini L; Cupini S; Masi G; Falcone A; Cremolini C
    Br J Cancer; 2021 Sep; 125(6):839-845. PubMed ID: 34253871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas.
    Boonpipattanapong T; Chewatanakornkul S
    J Clin Gastroenterol; 2006 Aug; 40(7):592-5. PubMed ID: 16917399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
    Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
    Yu P; Zhou M; Qu J; Fu L; Li X; Cai R; Jin B; Teng Y; Liu J; Shi J; Zhang J
    BMC Cancer; 2018 Nov; 18(1):1076. PubMed ID: 30404612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Yoshino T; Obermannov√° R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
    Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of half-life of carcinoembryonic antigen (CEA) in prognosis prediction of colorectal cancer patients with preoperatively elevated CEA.
    Yuan SQ; Zhou ZW; Wan DS; Chen G; Lu ZH; Wang GQ; Pan ZZ
    Ai Zheng; 2008 Jun; 27(6):612-7. PubMed ID: 18570735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YAP Levels Combined with Plasma CEA Levels Are Prognostic Biomarkers for Early-Clinical-Stage Patients of Colorectal Cancer.
    Xu Z; Wang H; Gao L; Zhang H; Wang X
    Biomed Res Int; 2019; 2019():2170830. PubMed ID: 31886181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
    Colloca GA; Venturino A; Guarneri D
    Int J Colorectal Dis; 2019 Apr; 34(4):657-666. PubMed ID: 30671635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy.
    Manojlovic N; Savic G; Nikolic B; Rancic N
    World J Clin Cases; 2022 Jan; 10(3):899-918. PubMed ID: 35127905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait.
    Behbehani AI; Al-Sayer H; Farghaly M; Kanawati N; Mathew A; al-Bader A; Van Dalen A
    Int J Biol Markers; 2000; 15(1):51-5. PubMed ID: 10763141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.
    Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(44):388-92. PubMed ID: 11995458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy.
    Liu S; Zhang Y; Lin Y; Wang P; Pan Y
    Front Immunol; 2022; 13():981527. PubMed ID: 36119063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of related factors of prognosis after surgical treatment of patients with non-metastatic colorectal cancer and construction of a normagram prediction model].
    Liu SX; Zhang L; Shi YK; Han XH
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):167-172. PubMed ID: 35184461
    [No Abstract]   [Full Text] [Related]  

  • 38. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma.
    Arnaud JP; Koehl C; Adloff M
    Dis Colon Rectum; 1980 Apr; 23(3):141-4. PubMed ID: 7379666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 40. Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and CEA as the Potential Prognostic Biomarkers for Colorectal Cancer.
    Ming-Sheng F; Mei-Ling D; Xun-Quan C; Yuan-Xin H; Wei-Jie Z; Qin-Cong P
    Can J Gastroenterol Hepatol; 2022; 2022():3109165. PubMed ID: 35028301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.